Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PXT3003 (baclofen) is a novel fixed-dose synergistic combination of baclofen, naltrexone and sorbitol formulated as an oral solution given twice a day for the treatment of Charcot-Marie-Tooth disease type 1A.
Product Name : PXT3003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2022
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PXT3003 (baclofen) completed an international Phase III trial with positive topline results for the treatment of CharcotMarie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States.
Product Name : PXT3003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2022
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New data from the ongoing Open-Label Phase III Extension Study of PXT3003 (baclofen), the PLEO-CMT-FU trial, suggest good safety profile and continuous treatment effect of PXT3003 measured on the Overall Neuropathy Limitation Scale after 5 years of total...
Product Name : PXT3003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 16, 2022
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Neovacs
Deal Size : $20.0 million
Deal Type : Financing
Details : The financing by Neovacs will support Pharnext operations and cash requirements, in particular the Phase III PREMIER pivotal study assessing its PTX3003 (baclofen) candidate in CMT1A, a rare debilitating peripheral neuropathy with currently no existing a...
Product Name : PXT3003
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 10, 2022
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Neovacs
Deal Size : $20.0 million
Deal Type : Financing
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PXT3003 is a novel fixed-dose synergistic combination of baclofen, naltrexone and sorbitol formulated as an oral solution given twice a day used in Charcot-Marie-Tooth Disease Type 1A.
Product Name : PXT3003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2021
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Alpha Blue Ocean
Deal Size : $96.0 million
Deal Type : Financing
Alpha Blue Ocean & Pharnext Announce the Signing of a Financing Agreement for up to 81 Million Euros
Details : This financing agreement for up to 81 million euros will enable Pharnext to strengthen its cash position and continue to develop its pivotal Phase III clinical trial of PXT3003, the PREMIER trial, in Charcot-Marie-Tooth disease type 1A (CMT1A).
Product Name : PXT3003
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 06, 2021
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Alpha Blue Ocean
Deal Size : $96.0 million
Deal Type : Financing
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The new results announced today continue to show sustained treatment benefits for CMT1A patients treated with PXT3003 at High Dose (‘HD’) in the PLEO-CMT-FU Period 2 trial with a data readout at 54 months of total trial time (double-blind + open-labe...
Product Name : PXT3003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2021
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PXT3003 is a novel drug candidate for the treatment of CMT1A and has been granted both Orphan Drug Designation and Fast Track Designation by the US Food and Drug Administration.
Product Name : PXT3003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2020
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharnext Receives Promising Innovative Medicine Designation for PXT3003
Details : All existing data indicate that PXT3003 is a safe and well tolerated drug combination.
Product Name : PXT3003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2020
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable